INTRODUCTION: To facilitate the clinical translation of (18)F-fluoroacetate ((18)F-FACE), the pharmacokinetics, biodistribution, radiolabeled metabolites, radiation dosimetry, and pharmacological safety of diagnostic doses of (18)F-FACE were determined in non-human primates. METHODS: (18)F-FACE was synthesized using a custom-built automated synthesis module. Six rhesus monkeys (three of each sex) were injected intravenously with (18)F-FACE (165.4 ± 28.5 MBq), followed by dynamic positron emission tomography (PET) imaging of the thoracoabdominal area during 0-30 min post-injection and static whole-body PET imaging at 40, 100, and 170 min. Serial blood samples and a urine sample were obtained from each animal to determine the time course of (18)F-FACE and its radiolabeled metabolites. Electrocardiograms and hematology analyses were obtained to evaluate the acute and delayed toxicity of diagnostic dosages of (18)F-FACE. The time-integrated activity coefficients for individual source organs and the whole body after administration of (18)F-FACE were obtained using quantitative analyses of dynamic and static PET images and were extrapolated to humans. RESULTS: The blood clearance of (18)F-FACE exhibited bi-exponential kinetics with half-times of 4 and 250 min for the fast and slow phases, respectively. A rapid accumulation of (18)F-FACE-derived radioactivity was observed in the liver and kidneys, followed by clearance of the radioactivity into the intestine and the urinary bladder. Radio-HPLC analyses of blood and urine samples demonstrated that (18)F-fluoride was the only detectable radiolabeled metabolite at the level of less than 9% of total radioactivity in blood at 180 min after the (18)F-FACE injection. The uptake of free (18)F-fluoride in the bones was insignificant during the course of the imaging studies. No significant changes in ECG, CBC, liver enzymes, or renal function were observed. The estimated effective dose for an adult human is 3.90-7.81 mSv from the administration of 185-370 MBq of (18)F-FACE. CONCLUSIONS: The effective dose and individual organ radiation absorbed doses from administration of a diagnostic dosage of (18)F-FACE are acceptable. From a pharmacologic perspective, diagnostic dosages of (18)F-FACE are non-toxic in primates and, therefore, could be safely administered to human patients for PET imaging.
INTRODUCTION: To facilitate the clinical translation of (18)F-fluoroacetate ((18)F-FACE), the pharmacokinetics, biodistribution, radiolabeled metabolites, radiation dosimetry, and pharmacological safety of diagnostic doses of (18)F-FACE were determined in non-human primates. METHODS: (18)F-FACE was synthesized using a custom-built automated synthesis module. Six rhesus monkeys (three of each sex) were injected intravenously with (18)F-FACE (165.4 ± 28.5 MBq), followed by dynamic positron emission tomography (PET) imaging of the thoracoabdominal area during 0-30 min post-injection and static whole-body PET imaging at 40, 100, and 170 min. Serial blood samples and a urine sample were obtained from each animal to determine the time course of (18)F-FACE and its radiolabeled metabolites. Electrocardiograms and hematology analyses were obtained to evaluate the acute and delayed toxicity of diagnostic dosages of (18)F-FACE. The time-integrated activity coefficients for individual source organs and the whole body after administration of (18)F-FACE were obtained using quantitative analyses of dynamic and static PET images and were extrapolated to humans. RESULTS: The blood clearance of (18)F-FACE exhibited bi-exponential kinetics with half-times of 4 and 250 min for the fast and slow phases, respectively. A rapid accumulation of (18)F-FACE-derived radioactivity was observed in the liver and kidneys, followed by clearance of the radioactivity into the intestine and the urinary bladder. Radio-HPLC analyses of blood and urine samples demonstrated that (18)F-fluoride was the only detectable radiolabeled metabolite at the level of less than 9% of total radioactivity in blood at 180 min after the (18)F-FACE injection. The uptake of free (18)F-fluoride in the bones was insignificant during the course of the imaging studies. No significant changes in ECG, CBC, liver enzymes, or renal function were observed. The estimated effective dose for an adult human is 3.90-7.81 mSv from the administration of 185-370 MBq of (18)F-FACE. CONCLUSIONS: The effective dose and individual organ radiation absorbed doses from administration of a diagnostic dosage of (18)F-FACE are acceptable. From a pharmacologic perspective, diagnostic dosages of (18)F-FACE are non-toxic in primates and, therefore, could be safely administered to humanpatients for PET imaging.
Authors: Nobuyuki Oyama; Tom R Miller; Farrokh Dehdashti; Barry A Siegel; Keith C Fischer; Jeff M Michalski; Adam S Kibel; Gerald L Andriole; Joel Picus; Michael J Welch Journal: J Nucl Med Date: 2003-04 Impact factor: 10.057
Authors: Gary J Kelloff; John M Hoffman; Bruce Johnson; Howard I Scher; Barry A Siegel; Edward Y Cheng; Bruce D Cheson; Joyce O'shaughnessy; Kathryn Z Guyton; David A Mankoff; Lalitha Shankar; Steven M Larson; Caroline C Sigman; Richard L Schilsky; Daniel C Sullivan Journal: Clin Cancer Res Date: 2005-04-15 Impact factor: 12.531
Authors: Datta E Ponde; Carmen S Dence; Nobuyuki Oyama; Joonyoung Kim; Yuan-Chuan Tai; Richard Laforest; Barry A Siegel; Michael J Welch Journal: J Nucl Med Date: 2007-03 Impact factor: 10.057
Authors: Morten Busk; Michael R Horsman; Steen Jakobsen; Johan Bussink; Albert van der Kogel; Jens Overgaard Journal: Eur J Nucl Med Mol Imaging Date: 2008-08-06 Impact factor: 9.236
Authors: Stefan A J Timmer; Tjeerd Germans; Marco J W Götte; Iris K Rüssel; Pieter A Dijkmans; Mark Lubberink; Jurrien M ten Berg; Folkert J ten Cate; Adriaan A Lammertsma; Paul Knaapen; Albert C van Rossum Journal: Eur J Nucl Med Mol Imaging Date: 2010-01-13 Impact factor: 9.236
Authors: Hsin-Hsien Yeh; Mei Tian; Rainer Hinz; Daniel Young; Alexander Shavrin; Uday Mukhapadhyay; Leo G Flores; Julius Balatoni; Suren Soghomonyan; Hwan J Jeong; Ashutosh Pal; Rajesh Uthamanthil; James N Jackson; Ryuichi Nishii; Hiroshi Mizuma; Hirotaka Onoe; Shinya Kagawa; Tatsuya Higashi; Nobuyoshi Fukumitsu; Mian Alauddin; William Tong; Karl Herholz; Juri G Gelovani Journal: Neuroimage Date: 2012-09-17 Impact factor: 6.556
Authors: Taylor R Kavanagh; William J Mischler; Eline E Verwer; You Feng; Kazue Takahashi; Shuyan Wang; Timothy M Shoup; Ramesh Neelamegam; Jing Yang; Nicolas J Guehl; Chongzhao Ran; Walter Massefski; Ye Cui; Souheil El-Chemaly; Peter M Sadow; William M Oldham; Marie F Kijewski; Georges El Fakhri; Marc D Normandin; Carmen Priolo Journal: Clin Cancer Res Date: 2018-07-27 Impact factor: 12.531
Authors: David W Brammer; Patrick J Gillespie; Mei Tian; Daniel Young; Muthuswamy Raveendran; Lawrence E Williams; Mihai Gagea; Fernando J Benavides; Carlos J Perez; Russell R Broaddus; Bruce J Bernacky; Kirstin F Barnhart; Mian M Alauddin; Manoop S Bhutani; Richard A Gibbs; Richard L Sidman; Renata Pasqualini; Wadih Arap; Jeffrey Rogers; Christian R Abee; Juri G Gelovani Journal: Proc Natl Acad Sci U S A Date: 2018-02-28 Impact factor: 11.205